Literature DB >> 31221303

Bleeding Complications in Lower-Extremity Peripheral Vascular Interventions: Insights From the NCDR PVI Registry.

Bhaskar Bhardwaj1, John A Spertus2, Kevin F Kennedy3, W Schuyler Jones4, David Safley3, Thomas T Tsai5, Herbert D Aronow6, Amit N Vora4, Yashashwi Pokharel2, Arun Kumar7, Robert R Attaran8, Dmitriy N Feldman9, Ehrin Armstrong10, Anand Prasad11, Bruce Gray12, Adam C Salisbury13.   

Abstract

OBJECTIVES: This study sought to assess periprocedural bleeding complications in lower-extremity peripheral vascular interventions (PVIs).
BACKGROUND: Few studies have examined the incidence, predictors, or outcomes of periprocedural bleeding after lower-extremity PVI.
METHODS: The study examined patients undergoing PVI at 76 hospitals in the National Cardiovascular Data Registry PVI registry from 2014 to 2016. Post-PVI major bleeding was defined as any overt bleeding with a hemoglobin (Hb) drop of ≥3 g/dl, any Hb decline of ≥4 g/dl, or blood transfusion in patients with pre-procedure Hb >8 g/dl within 72 h of their procedure. Hierarchical multivariable logistic regression was used to identify factors independently associated with post-PVI bleeding. The study also examined adjusted in-hospital mortality among patients with or without major bleeding complications.
RESULTS: Among 18,289 PVI procedures, major bleeding occurred in 744 (4.10%). Patient characteristics independently associated with bleeding included age, female sex, heart failure, pre-procedural hemoglobin <12 g/dl, nonelective PVI, and critical limb ischemia on presentation. Procedural characteristics associated with bleeding included nonfemoral vascular access, use of thrombolytic therapy, PVI of the aortoiliac segment, and multilesion interventions, whereas use of closure devices was associated with less bleeding. All-cause in-hospital mortality was higher in patients who experienced bleeding than in those who did not (6.60% vs. 0.30%; p < 0.001; adjusted hazard ratio: 10.9; 95% confidence interval: 6.9 to 17.0).
CONCLUSIONS: Major bleeding occurred in 4.10% of lower-extremity PVI procedures and was associated with several patient and procedural characteristics, as well as in-hospital mortality. These insights can be incorporated into strategies to reduce periprocedural bleeding after PVI.
Copyright © 2019 American College of Cardiology Foundation. All rights reserved.

Entities:  

Keywords:  peripheral arterial disease; peripheral vascular interventions; periprocedural bleeding

Year:  2019        PMID: 31221303      PMCID: PMC7176493          DOI: 10.1016/j.jcin.2019.03.012

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  31 in total

1.  In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant.

Authors:  Nicolas W Shammas; Jon H Lemke; Eric J Dippel; Dawn E McKinney; Vickie S Takes; Monica Youngblut; Melodee Harris; Catherine Harb; Matthew J Kapalis; Jane Holden
Journal:  J Invasive Cardiol       Date:  2003-05       Impact factor: 2.022

2.  Longitudinal Risk of Adverse Events in Patients With Acute Kidney Injury After Percutaneous Coronary Intervention: Insights From the National Cardiovascular Data Registry.

Authors:  Javier A Valle; Lisa A McCoy; Thomas M Maddox; John S Rumsfeld; P Michael Ho; Ivan P Casserly; Brahmajee K Nallamothu; Matthew T Roe; Thomas T Tsai; John C Messenger
Journal:  Circ Cardiovasc Interv       Date:  2017-04       Impact factor: 6.546

3.  Patterns of treatment for peripheral arterial disease in the United States: 1996-2005.

Authors:  Vincent L Rowe; William Lee; Fred A Weaver; David Etzioni
Journal:  J Vasc Surg       Date:  2009-04       Impact factor: 4.268

4.  Safety of contemporary percutaneous peripheral arterial interventions in the elderly insights from the BMC2 PVI (Blue Cross Blue Shield of Michigan Cardiovascular Consortium Peripheral Vascular Intervention) registry.

Authors:  Benjamin R Plaisance; Khan Munir; David A Share; M Ashraf Mansour; James M Fox; Paul G Bove; Arthur L Riba; Stanley J Chetcuti; Hitinder S Gurm; P Michael Grossman
Journal:  JACC Cardiovasc Interv       Date:  2011-06       Impact factor: 11.195

5.  Association of Anemia With Outcomes in Patients Undergoing Percutaneous Peripheral Vascular Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2 VIC).

Authors:  Nikhil V Ambulgekar; Scott F Grey; Howard S Rosman; Hussein Othman; Thomas P Davis; Timothy J Nypaver; Theodore Schreiber; Hiroshi Yamasaki; Thomas A Lalonde; Peter K Henke; Hitinder S Gurm; Rajendra H Mehta; P Michael Grossman
Journal:  J Invasive Cardiol       Date:  2018-01       Impact factor: 2.022

6.  In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™.

Authors:  Robin Mathews; Eric D Peterson; Anita Y Chen; Tracy Y Wang; Chee Tang Chin; Gregg C Fonarow; Christopher P Cannon; John S Rumsfeld; Matthew T Roe; Karen P Alexander
Journal:  Am J Cardiol       Date:  2011-02-15       Impact factor: 2.778

7.  Association between bleeding events and in-hospital mortality after percutaneous coronary intervention.

Authors:  Adnan K Chhatriwalla; Amit P Amin; Kevin F Kennedy; John A House; David J Cohen; Sunil V Rao; John C Messenger; Steven P Marso
Journal:  JAMA       Date:  2013-03-13       Impact factor: 56.272

8.  Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry.

Authors:  Jason B Lindsey; Steven P Marso; Michael Pencina; Joshua M Stolker; Kevin F Kennedy; Charanjit Rihal; Greg Barsness; Robert N Piana; Steven L Goldberg; Donald E Cutlip; Neal S Kleiman; David J Cohen
Journal:  JACC Cardiovasc Interv       Date:  2009-11       Impact factor: 11.195

9.  Impact of sex on morbidity and mortality rates after lower extremity interventions for peripheral arterial disease: observations from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium.

Authors:  Elizabeth A Jackson; Khan Munir; Theodore Schreiber; Jeffrey R Rubin; Robert Cuff; Katherine A Gallagher; Peter K Henke; Hitinder S Gurm; P Michael Grossman
Journal:  J Am Coll Cardiol       Date:  2014-04-23       Impact factor: 24.094

10.  The Association of Peri-Procedural Blood Transfusion with Morbidity and Mortality in Patients Undergoing Percutaneous Lower Extremity Vascular Interventions: Insights from BMC2 VIC.

Authors:  Peter K Henke; Yeo Jung Park; Sachinder Hans; Paul Bove; Robert Cuff; Andris Kazmers; Theodore Schreiber; Hitinder S Gurm; P Michael Grossman
Journal:  PLoS One       Date:  2016-11-11       Impact factor: 3.240

View more
  4 in total

1.  Acute Kidney Injury Following In-Patient Lower Extremity Vascular Intervention: From the National Cardiovascular Data Registry.

Authors:  David M Safley; Adam C Salisbury; Thomas T Tsai; Eric A Secemsky; Kevin F Kennedy; R Kevin Rogers; Faisal Latif; Nicolas W Shammas; Lawrence Garcia; Matthew A Cavender; Kenneth Rosenfield; Anand Prasad; John A Spertus
Journal:  JACC Cardiovasc Interv       Date:  2021-02-08       Impact factor: 11.195

Review 2.  Assessing health-related quality of life among patients with peripheral artery disease: A review of the literature and focus on patient-reported outcome measures.

Authors:  Aishwarya Raja; John Spertus; Robert W Yeh; Eric A Secemsky
Journal:  Vasc Med       Date:  2020-12-09       Impact factor: 3.239

3.  Hematoma Resolution In Vivo Is Directed by Activating Transcription Factor 1.

Authors:  Anusha Seneviratne; Yumeng Han; Eunice Wong; Edward R H Walter; Lijun Jiang; Luke Cave; Nicholas J Long; David Carling; Justin C Mason; Dorian O Haskard; Joseph J Boyle
Journal:  Circ Res       Date:  2020-07-01       Impact factor: 17.367

4.  Preliminary Results of the Outpatient Endovascular and Interventional Society National Registry.

Authors:  Samuel S Ahn; Robert W Tahara; Lauren E Jones; Jeffrey G Carr; John Blebea
Journal:  J Endovasc Ther       Date:  2020-08-19       Impact factor: 3.487

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.